These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 2893655

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET.
    Boecker H, Ceballos-Baumann A, Bartenstein P, Weindl A, Siebner HR, Fassbender T, Munz F, Schwaiger M, Conrad B.
    Brain; 1999 Sep; 122 ( Pt 9)():1651-65. PubMed ID: 10468505
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Somatostatin is increased in the basal ganglia in Huntington disease.
    Aronin N, Cooper PE, Lorenz LJ, Bird ED, Sagar SM, Leeman SE, Martin JB.
    Ann Neurol; 1983 May; 13(5):519-26. PubMed ID: 6191621
    [Abstract] [Full Text] [Related]

  • 9. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.
    Bartzokis G, Tishler TA.
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):821-33. PubMed ID: 10875443
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin is increased in the nucleus accumbens in Huntington's disease.
    Beal MF, Bird ED, Langlais PJ, Martin JB.
    Neurology; 1984 May; 34(5):663-6. PubMed ID: 6143284
    [Abstract] [Full Text] [Related]

  • 11. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD.
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, Martin JB.
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease.
    Pittaway KM, Reynolds GP, Emson PC.
    J Neurochem; 1984 Sep; 43(3):878-80. PubMed ID: 6235325
    [Abstract] [Full Text] [Related]

  • 19. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.
    Mann DM, Oliver R, Snowden JS.
    Acta Neuropathol; 1993 Sep; 85(5):553-9. PubMed ID: 8493863
    [Abstract] [Full Text] [Related]

  • 20. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.
    Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ.
    Neurology; 1994 May; 44(5):823-8. PubMed ID: 8190282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.